Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies

Phase 1

Conditions: Stage IV Gastric Carcinoma
Stage IV Nasopharyngeal Carcinoma
T-Cell Lymphoma Stage IV
Stage IV Adult Hodgkin Lymphoma
Stage IV Diffuse Large B-Cell Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Interleukin-2

First Posted Date: 2017-02-07

Last Posted Date: 2017-05-02

Lead Sponsor: Yang Yang

Target Recruit Count: 20

Registration Number: NCT03044743

Locations: 🇨🇳
The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China

Umbilical Cord Blood Transplantation From Unrelated Donors

Phase 1

Recruiting

Conditions: Metabolism Disorder
Lymphoma
Aplastic Anemia
Acute Leukemia
Myelodysplastic Syndromes
Congenital Hematological Disorder
Chronic Leukemia
Multiple Myeloma
Immune Deficiency Disorder
Solid Tumor

Interventions: Procedure: Cord Blood Infusion
Radiation: Total Body Irradiation 200 cGy
Radiation: Total Body Irradiation 1200 cGy
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Mesna
Drug: Melphalan
Drug: Busulfan

First Posted Date: 2017-01-11

Last Posted Date: 2024-08-19

Lead Sponsor: University of Rochester

Target Recruit Count: 30

Registration Number: NCT03016806

Locations: 🇺🇸
Wilmot Cancer Institute, Rochester, New York, United States

The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma

Phase 2

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Bortezomib
Drug: Fludarabine
Drug: Cytarabine

First Posted Date: 2017-01-11

Last Posted Date: 2017-01-11

Lead Sponsor: Tingbo Liu

Target Recruit Count: 50

Registration Number: NCT03016988

Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma
Acute Leukemia in Remission
Hodgkin Lymphoma
Chronic Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Multiple Myeloma
Primary Myelofibrosis
Myelodysplastic Syndromes

Interventions: Drug: Fludarabine
Drug: Busulfan
Drug: Cyclophosphamide
Radiation: Total body irradiation (TBI)
Procedure: Peripheral Blood Hematopoietic Cell Transplantation (HCT)
Drug: Sirolimus (SIR)
Drug: Mycophenolate mofetil (MMF)
Drug: Granulocyte-colony stimulating factor (G-CSF)

First Posted Date: 2017-01-11

Last Posted Date: 2021-09-16

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 32

Registration Number: NCT03018223

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Phase 1

Recruiting

Conditions: Acute Lymphoblastic Leukemia
Immune System Diseases
Immunoproliferative Disorders

Interventions: Biological: iC9-CAR19 cells
Drug: Rimiducid
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2017-01-10

Last Posted Date: 2024-10-26

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 54

Registration Number: NCT03016377

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

Phase 2

Completed

Conditions: Neoplasms

Interventions: Drug: letetresgene autoleucel (GSK3377794)
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2016-12-14

Last Posted Date: 2023-04-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 23

Registration Number: NCT02992743

Locations: 🇺🇸
GSK Investigational Site, Houston, Texas, United States

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Aplastic Anemia
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Myelomonocytic Leukemia
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Lymphoblastic Lymphoma
Myelodysplastic Syndrome
Myeloproliferative Neoplasm

Interventions: Drug: Cyclophosphamide
Biological: Filgrastim
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Biological: Rituximab
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2016-11-09

Last Posted Date: 2023-02-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT02960646

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)

Phase 1

Completed

Conditions: Solid Cancer

Interventions: Biological: TSA-CTL
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2016-11-09

Last Posted Date: 2023-02-02

Lead Sponsor: BGI, China

Target Recruit Count: 11

Registration Number: NCT02959905

Locations: 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine
Biological: Obinutuzumab
Drug: Cyclophosphamide
Drug: Venetoclax
Biological: Rituximab
Drug: Ibrutinib
Drug: Bendamustine

First Posted Date: 2016-10-31

Last Posted Date: 2024-12-30

Lead Sponsor: German CLL Study Group

Target Recruit Count: 926

Registration Number: NCT02950051

Locations: 🇮🇱
Kaplan Medical Center, Rechovot, Israel
🇳🇱
Canisius-Wilhelmina ZH, Nijmegen, Netherlands
🇳🇱
Antonius Ziekenhuis Sneek, Sneek, Netherlands

and more 158 locations

Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme

Phase 1

Conditions: Glioblastoma Multiforme

Interventions: Biological: Anti-PD-L1 CSR T cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2016-10-19

Last Posted Date: 2016-10-19

Lead Sponsor: Beijing Sanbo Brain Hospital

Target Recruit Count: 20

Registration Number: NCT02937844

Locations: 🇨🇳
Sanbo Brain Hospital Capital Medical University, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy